Bin Liu, Ph.D.
Dr. Liu is globally recognized for his research in antibody-based cancer therapeutics. He is a professor at University of California, San Francisco and the principle investigator at the Helen Diller Family Comprehensive Cancer Center at UCSF. His discovery of a unique approach to treating prostate cancer and multiple myeloma led to the creation in 2016 of biopharmaceutical company Fortis Therapeutics. Dr. Liu is highly involved in the national cancer therapeutics community, serving as a member of the UCSF Stephen and Nancy Grand Multiple Myeloma Translational Initiative, the Sean Parker Institute for Cancer Immunotherapy and other organizations. He holds a B.A. in Molecular Biology and Biochemical Sciences from Princeton University and a doctorate in Biochemistry and Biophysics from UCSF. He is the recipient of more than a dozen scientific honors and has authored more than 20 articles in peer-reviewed journals.